Clinical-stage biopharma company Elevation Oncology announced an underwritten public offering of 17.8 million common shares and pre-funded warrants to purchase up to 4.4 million common shares. The company is targeting to raise gross proceeds of approximately USD 50 million at a price of USD 2.25 per share. The offering window is expected to close on June 15, 2023.
The net proceeds from the offering will primarily be used to fund the clinical development of EO-3021, Elevation Oncology's lead product candidate, which is an antibody-drug conjugate designed to target cancer cells expressing Claudin 18.2. The funds will also be used for general corporate purposes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.